Selecting the Appropriate Patients and Monitoring Responses to CAR T-Cell Therapy in LBCL

Phase 3 data show that nivolumab/AVD may also reduce long-term toxicities vs brentuximab vedotin/AVD in advanced Hodgkin lymphoma.

Leaders from the lymphoma space highlight the importance of mentorship in establishing their careers and impart advice to women looking to advance theirs.

Nausheen Ahmed, MD, discusses the FDA REMS mandate to help assess toxicity in patients receiving CAR T-cell therapy.

Bispecific antibodies including epcoritamab have “a lot of potential for upward mobility” in lymphoma, according to Tycel Phillips, MD.

Treatment with valemetostat yields responses across all PTCL subtypes in the phase 2 VALENTINE-PTCL01 trial.

Efficacy, safety, time, and cost were all factors assessed between subcutaneous and intravenous rituximab for patients with non-Hodgkin lymphoma.